Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

• Status: Recruiting
• Trial end date: 2023-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The participants are being treated with Tumor Treating Fields (TTFields) for malignant glioma, and this type of treatment may cause skin-related side effects. This study will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects of TTFields.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Treatments: Clindamycin; Clindamycin palmitate; Clindamycin phosphate; Triamcinolone; Triamcinolone Acetonide; Triamcinolone diacetate; Triamcinolone hexacetonide

Criteria

Inclusion Criteria:

• Age ≥18 years

• Diagnosis of newly diagnosed GBM with plan to initiate treatment with TTFields with or without systemic therapy, confirmed by the enrolling institution

• Able to self-administer topical interventions or has available another person who can apply the topical agents

• Treatment with TTF should be initiated within 7 days of planned initiation on this trial.

Exclusion Criteria:

• Known history of allergy to any ingredient of the study agents

• Preexisting scalp disorders such as psoriasis or dermatitis that, in the opinion of the investigator, will affect the grading of skin adverse events, confirmed by enrolling institution.

• Use of concurrent topical therapy to the scalp for another dermatologic condition

• Active, uncontrolled infection requiring systemic or oral antibiotic therapy within 14 days of enrollment

• Use of dexamethasone 2mg a day or greater within 14 days of enrollment

• Recurrent GBM or malignant glioma

• Concurrent administration of bevacizumab

• Pregnant Women